Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1132036

registered interest
date	13/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Primary Care Networks
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what criteria his Department plans to use to assess Primary Care Networks’ engagement with local communities.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	264407
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>For Primary Care Networks (PCNs) to be successful they will need to work in partnership with local people and the communities they serve. NHS England does have a statutory duty to undertake an annual assessment of clinical commissioning groups’ (CCGs) performance, as part of the CCG Improvement and Assessment Framework (IAF). One of the indicators assessed is patient and community engagement. All NHS service providers, including general practitioner practices, have legal duties to engage with local authority health scrutiny about changes which may be considered substantial. These duties which currently apply to NHS service providers and commissioners around engagement and consultation will continue to be valid.</p><p>Further information on the IAF is available on the NHS England website at the following link:</p><p><a href="https://www.england.nhs.uk/commissioning/regulation/ccg-assess/" target="_blank">https://www.england.nhs.uk/commissioning/regulation/ccg-assess/</a></p><p>Results from the assessments are published on ‘MyNHS’ at the following link:</p><p><a href="https://www.nhs.uk/service-search/performance-indicators/organisations/ccg-year-end-2015-assurance-assessment" target="_blank">https://www.nhs.uk/service-search/performance-indicators/organisations/ccg-year-end-2015-assurance-assessment</a></p><p>The assessments made are in line with the document ‘Patient and public participation in commissioning health and care: statutory guidance for CCGs and NHS England’, which is at the following link:</p><p><a href="https://www.england.nhs.uk/publication/patient-and-public-participation-in-commissioning-health-and-care-statutory-guidance-for-ccgs-and-nhs-england/" target="_blank">https://www.england.nhs.uk/publication/patient-and-public-participation-in-commissioning-health-and-care-statutory-guidance-for-ccgs-and-nhs-england/</a></p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 20/06/2019 15:40:56 answering member 4455 label Biography information for Seema Kennedy
tabling member	4249 label Biography information for Anne Marie Morris

1131740

registered interest
date	12/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, which topics have been identified for inclusion in the upcoming review of the appraisal methods used by NICE.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	263870
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 263871 263872 263873 263874 question first answered 20/06/2019 13:18:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	4382 label Biography information for Daniel Zeichner

1131742

registered interest
date	12/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the timescale is for NICE's Methods review.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	263871
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 263870 263872 263873 263874 question first answered 20/06/2019 13:18:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	4382 label Biography information for Daniel Zeichner

1131743

registered interest
date	12/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether changes to NICE’s appraisal methods identified during the NICE Methods review will be cost-neutral.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	263872
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 263870 263871 263873 263874 question first answered 20/06/2019 13:18:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	4382 label Biography information for Daniel Zeichner

1131744

registered interest
date	12/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what criteria was used by NICE to determine which patient organisations were offered membership of the NICE Methods Working Group.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	263873
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 263870 263871 263872 263874 question first answered 20/06/2019 13:18:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	4382 label Biography information for Daniel Zeichner

1131746

registered interest
date	12/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what opportunities there will be for patient groups that are not part of the NICE Methods Working Group to take part in the task and finish groups.
tabling member constituency	Cambridge
tabling member printed	Daniel Zeichner
uin	263874
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for the methods and processes used in the development of its technology appraisal and highly specialised technologies recommendations. NICE has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access.</p><p> </p><p>The Voluntary Scheme states that industry and other relevant stakeholders will be active participants in the review, including inputting on scope, participating in working discussions, and providing views on recommendations. NICE’s updated methods guide will also be subject to a public consultation.</p><p> </p><p>NICE has established a working group, consisting of members from NICE, NHS England, the Department, patient organisations and the life sciences industry. The working group reports to a steering group, chaired by NICE and with members from NHS England, the Department, and an independent academic methodologist. The steering group will present its recommendations to NICE’s Senior Management Team, which in turn will report to the NICE Board. NICE approached patient groups with experience of NICE and its processes and methods. There are three patient group representatives on the working group with a wide range of experience, covering a range of topic areas, reflecting the programmes under review. Membership of the working group will be published in due course.</p><p> </p><p>NICE is now in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations with input from the working group and steering group. The scope of the review - a list of the aspects of NICE’s current methods that will be considered in the review - will be presented to the NICE Board in July. Additional detail and more information will be made available on the NICE website in due course. NICE anticipates being in a position to confirm the revised methods guide by the end of 2020, following public consultation.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 263870 263871 263872 263873 question first answered 20/06/2019 13:18:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	4382 label Biography information for Daniel Zeichner

1131830

registered interest
date	12/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Fungal Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the risks to patient health posed by fungal infections; and what steps he is taking to tackle those risks.
tabling member constituency	Warley
tabling member printed	John Spellar
uin	263692
answer	answer is ministerial correction date of answer 20/06/2019 answer text <p>The most common invasive fungal infection in the United Kingdom is blood stream infection with yeast, often following surgical interventions. Public Health England (PHE) has prepared advisory documentation for national dissemination and individual hospital response following recent outbreaks caused by this organism, which can be viewed at the following link:</p><p><a href="https://www.gov.uk/government/publications/candida-auris-emergence-in-england/candida-auris-within-the-united-kingdom-updated-guidance-published" target="_blank">https://www.gov.uk/government/publications/candida-auris-emergence-in-england/candida-auris-within-the-united-kingdom-updated-guidance-published</a></p><p>Invasive mould infections such as invasive aspergillosis are more often seen in patients with haematological malignancies or those undergoing treatment for them, and it is difficult to capture absolute data on the incidence of these due to difficulty in definitive diagnosis.</p><p>Chronic yeast infections are frequently seen in females that have suffered recurrent bouts of vaginal candidosis (thrush). Estimates suggest that 70% of women report having had at least one episode whilst 8% have repeated and persistent infections. Dermatophyte infections, including athletes’ foot are extremely common, found in about 10% of the adult population at any one time. Scalp and nail infections with these organisms are more disfiguring and difficult to treat.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 20/06/2019 15:39:41 answering member 4455 label Biography information for Seema Kennedy
tabling member	318 label Biography information for John Spellar